Governor Mike DeWine (R) signed Executive Order 2022-05D to suspend the normal rulemaking process to allow the Ohio Board of Pharmacy to classify several bezimidazole-opioids as Schedule One drugs, meaning they have no accepted medical use in treatment and pose an imminent hazard to public health, safety, and welfare.
Also in Ohio, The Department of Medicaid (ODM (Ohio Department of Medicaid)) has posted the slides from its most recent pharmacy stakeholder online seminar that outlines their future process for reimbursing pharmacies for Specialty Drugs under the Managed Care Single Pharmaceutical Benefits Manager Program (SPBM). Additionally, ODM announced that the implementation of the SPBM program has been delayed until October of 2022. More information can be found on the SPBM webpage. Members should expect ODM to schedule the next online seminar, on which ODM intends to announce new pharmacy rates, to be scheduled for the week of May 16. NACDS will email the invite to members operating in Ohio as soon as we receive it.
For more information, contact NACDS’ Jill McCormack at 717-592-8977.